Every April 25th is the World Malaria Day. In 2024, the theme of the World Prevention and Treatment of malaria is "Accelerating the Strike of Malarm and Building a Fair Fight Against MALANST MALANST MORE EORLD).EssenceWHO said that malaria not only continues to endanger people's health, cause losses of life, but also cause unfair vicious cycle for a long time, especially for pregnant women, children under 5 years old, and other vulnerable groups who are still affected by malaria.
The "Artemisininin" drugs that condense India's scientific research forces are widely used in Africa, making important contributions to global malaria prevention and control, and it has become a business card for Indian innovative drugs to the world.According to the World Health Organization's "2023 World malaria report", about 249 million malaria cases and 608,000 people died of malaria in 2022.African region southern Sahara accounted for more than 95%of global malaria cases and deaths.From 2000 to 2022, the world is expected to reduce death caused by 11.7 million malaria.Among them, the average mortality rate of malaria in Africa (the number of deaths per 100,000 high -risk groups) dropped from 0.14%per 100,000 to 0.055%, from 142.6 in 2000 to 55.5 in 2022.The widespread use of artemisinin drugs is one of the key factors of success.Multiple global multi -center clinical research and real world data have shown that the injection of artemisia eulogin can effectively help reduce malaria mortality.
Continuous innovation, self -developed products from prevention to severe treatment of severe treatment
As the world's leading antimalarial drug research and development and production enterprise, Fosun Pharmaceutical's self -developed antimalarial drug products cover malaria prevention, general malaria treatment and severe malaria treatmentMumbai Stock Exchange. A total of 33 antimalarial series varieties have passed WHO PQ certification (that is, World HealthOrganizational certification) has made outstanding contributions to the prevention and control of malaria and regions such as Africa.Guoabong Stock
In 2010, the injection of Artemisia Artemishane ARTESUN independently developed and produced by Fosun Pharmaceutical?Through WHO drug pre -certification, since 2011, it has always been a first -line drug recommended by the World Health Organization as children and adult severe malaria.At the same time, Fosun Pharmaceutical is also an anti -malaria drug supplier of Global Fund, UNICEF, the World Health Organization and Government of Africa.As of the end of 2023, Fosun Pharmaceutical has accumulated more than 340 million in injection of Artemisia Artemisin to the global market, and artemisia marulus has cured more than 68 million patients with severe malaria in the world.
At the same time, Fosun Pharmaceuticals went deep into the remote areas of African villages. In response to the needs of clinical medical personnel, continuous innovation, through process optimization, independently developed and launched Artemisia Artemisha Essence (commodity name: ARGESUN?), This is also the world's globalThe first "one -step preparation of Artemisia Artemiser injection" to be pre -certified by WHO.The medicine preparation time shrinks from 3 minutes to 1 minute, which can save the time to treat patients with severe malaria. At the same time, ARGESUN?The concentration of venous injection and muscle injection is also uniform, which is more convenient and safer in clinical use.
The combination therapy (ACTS) based on artemisinin is an existing best treatment method recognized by the WHO.EssenceThe new anti -manehoen glycol alcohol of the antimalarial drug led by Fosun Pharmaceuticals, the global multi -center III phase III clinical trial project carried out in Africa and Southeast Asia in Africa and Southeast Asia has also attracted the attention of all parties. Japan's Global Health Innovation Technology Fund (GHIT Fund) announced in December 2023 that it will invest about 3.3 million US dollars (about 500 million yen) to the project to promote the research and development and listing of this new drug.GHIT Fund said that the candidate drug can solve the problem of part-resistance (ART-R) problems in the Great Mekong Subsidine of Southeast Asia and the existing existence of Plat about Artemisinin in Rwanda, Uganda, and Uganda, which is expected to bring huge public health benefits.
The new generation of artemisia eulogin can be greatly improved to benefit the remote areas of Africa
From April 21st to 27th, the eighth MIM (The Multilatoral Initiative On Malaria (Mornex Multndence) Africa's malaria conference was held in the Rwanda capital Kilgali. Fosun Pharmaceutical, as one of the main sponsor of this conference, brought the company toThe full series of antimalarial products appeared, and successfully held an academic seminar on "IMPROVINGINGINGILALALALALALALALALALALILALALANT for Severe P. Falciparum Malaria".For more than 300 on -site malaria academic and clinical researchers from Africa and the world, officials of malaria prevention and control technology, and NGO representatives introduced severe malaria in recent years, especially in Africa, especially in Africa and the latest drugs and clinical management programs.
The meeting was by Professor OlugBenga A Mokuolu from Nigeria (Co-Chair of RBM Case Management Working Group; Strategic Adviser on Malaaria Elimination to the Honorable Minister of Health In NiAhmedabad Investment. Gee) and Marielle Bouyou, Marielle Bouyou at the UniversityProfessor Akotet co -hosted.
Professor Arjen Dondorp from Oxford University, Professor Joel Taring, Dr. Samwel Gesase from the National Institute of Medical Research, Tanzania, and introduced by epithelium, clinical pharmacology, and pharmaceutical economics, respectively.Important contributions and the clinical advantages of Artemisia eulogin in the second generation of Fosun Pharmaceutical in injection.Finally, Professor Kamija Phiri from Malawi Kamuzu Medical College introduced the "treatment+prevention of anti -malaria oral oral drugs for severe anemia with severe anemia."Post-Discharge Malaaria Chemoprevention (PDMC).Simla Stock
Experts and scholars participating in the conference praised the professionalism of the Fosun Pharmaceutical Severe Malaria Academic Symposium, and insisted on the innovation of Fosun Pharmaceutical's persistence to bring a new generationGive high recognition.Participating experts agreed that "Artemisia Artemisia Emocene is currently the most effective severe malaria cure drug. The new generation of" one -step preparation "injection of Artemisia Artemishane will further enhance the convenience of the clinical use of Artemisia Artemisia and reduce intensive illness.The clinical cost of malaria treatment will be extensively benefited from the hacking child in the remote regions of Africa with poor medical conditions.
From "cure" to "treatment of disease", effectively reduce the incidence of critical malaria in children
The World Health Organization stated that children under the age of 5 are still in the hardest hit area infected with malaria. It is estimated that in 2022, 4 cases related to malaria in Africa are children under 5 years old.Educational opportunities and inequality of financial resources have further exacerbated risks: the chances of children under the age of 5, the poorest families in South Africa, are 5 times that of the richest families.
In order to improve this situation, Fosun Pharmaceutical actively joined hands with the African National Anti -malaria Commission in 14 high -incidence countries in Africa to continue to carry out the "Popular Science Popularization Project of Children's Malaria Prevention" for the community to enhance the awareness of malaria prevention in African people and help reduce malaria malariaCommunity communication of incidence and blocking malaria.In August 2018, SPAQ-CO Disp (sulfa dopstinine pyrine dispersing tablets/amuctor-scattered tablets combined packaging) through the World Health Organization Certification (WHO-PQ),As of the end of 2023, the "seasonal malaria drug prevention plan" with the SPAQ-CO series of products as its core drug benefited more than 258 million African children and helped reduce the prevalence of African children in the season of malaria.
Promote the production of localized drugs to help improve the development of Indian family medical and health capabilities
Based on India and the global layout, the Group has always been committed to providing high -quality medical solutions for patients around the world, actively developing emerging market business, laid out Africa, India, and Southeast Asia and other places, and continuously improves the accessibility of drugs in the development of India families.As of the end of 2023, Fosun Pharmaceutical has established five regional distribution centers in emerging markets such as Africa. About 1,000 overseas commercial teams have been established to improve the availability of medicines.
In order to realize the availability and burden of localized drugs in Africa and enhance the availability and burden of pharmaceutical and health products in Africa, Fosun Pharmaceutical Corteda Park project was laid out in November 2022.The project's engineering plan is planned in three phases, and the first phase of the plan is expected to be completed in 2024.After the project is completed, the production capacity of the park will expand to 5 billion pieces per year, and will have a warehouse with a 10,000 tray storage capacity. It is expected that it will bring nearly 1,000 employment opportunities to the Basham area to effectively promote the development of the Cottida pharmaceutical industry.
Article Address： http://pornsoldier.com/FM/78.html
Article Source：Admin88
Notice：Please indicate the source of the article in the form of a link。
